Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 22;22(3):81.
doi: 10.1208/s12249-021-01951-w.

Liquid Crystalline Phases for Enhancement of Oral Bioavailability

Xingwang Zhang  1 , Wei Wu  2   3
Affiliations
Review

Liquid Crystalline Phases for Enhancement of Oral Bioavailability

Xingwang Zhang et al. AAPS PharmSciTech. .

Abstract

Liquid crystalline phases (LCPs) are generated upon lipolysis of ingested lipids in the gastrointestinal tract. The breaking off and subsequent evolution of LCPs produce more advanced vesicular and micellar structures which facilitate oral absorption of lipids, as well as co-loaded drug entities. Owing to sustained or controlled drug release, bioadhesiveness, and capability of loading drugs of different properties, LCPs are promising vehicles to implement for enhancement of oral bioavailability. This review aims to provide an overview on the classification, preparation and characterization, in vivo generation and transformation, absorption mechanisms, and encouraging applications of LCPs in enhancement of oral bioavailability. In addition, we comment on the merits of LCPs as oral drug delivery carriers, as well as solutions to industrialization utilizing liquid crystalline precursor and preconcentrate formulations.

Keywords: cubosomes; drug delivery; hexosomes; in vivo fate; liquid crystalline phases; oral bioavailability.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Dierking I, Al-Zangana S. Lyotropic liquid crystal phases from anisotropic nanomaterials. Nanomaterials (Basel, Switzerland). 2017;7(10):305.
    1. Rajak P, Nath LK. B.Bhuyan. Liquid crystals: an approach in drug delivery. Indian J Pharm Sci. 2019;81(1):11–21.
    1. Lancelot A, Sierra T, Serrano JL. Nanostructured liquid-crystalline particles for drug delivery. Expert Opin Drug Deliv. 2014;11(4):547–64. - PubMed
    1. Otte A, Soh B-K, Yoon G, Park K. Liquid crystalline drug delivery vehicles for oral and IV/subcutaneous administration of poorly soluble (and soluble) drugs. Int J Pharm. 2018;539(1):175–83. - PubMed
    1. Madheswaran T, Kandasamy M, Bose RJ, Karuppagounder V. Current potential and challenges in the advances of liquid crystalline nanoparticles as drug delivery systems. Drug Discov Today. 2019;24(7):1405–12. - PubMed

LinkOut - more resources